Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy induced Vomiting in Children Receiving Highly Emetogenic Chemotherapy
NCT Number:
NCT03118986
Phase:
II
Protocol Type:
Supportive Care
Age Group:
Children
Disease Sites:
Other Hematopoietic
Study Objectives:
Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving hematopoietic stem cell transplant (HSCT) conditioning experience CINV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving high dose cyclophosphamide for hematopoietic stem cell transplantation (HSCT) conditioning.
Study Documents
(MUSC NetID required for document access)